Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Immunic ( ($IMUX) ) has shared an announcement. On April 9, 2025, Immunic, Inc. announced a securities purchase agreement with institutional and ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst F. Khurshid now expects that the ...

Analysts are intrested in these 5 stocks: ( ($IMUX) ), ( ($X) ), ( ($KLAC) ), ( ($IIPR) ) and ( ($GT) ). Here is a breakdown ...

NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Plus, a first-quarter stock and bond market wrap up. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

As of March 19, 2025, the average one-year price target for Immunic is $13.43/share. The forecasts range from a low of $5.05 to a high of $29.40. The average price target represents an increase of ...

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments ...

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments ...

NEW YORK, April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...